Vertex Pharmaceuticals (VRTX) Depreciation & Amortization (CF) (2009 - 2026)

Vertex Pharmaceuticals' Depreciation & Amortization (CF) history runs 18 years deep, the most recent figure standing at $55.9 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 15.5% year-over-year to $55.9 million; the TTM figure through Mar 2026 stood at $217.3 million (up 7.52% YoY), while the FY2025 annual figure was $209.8 million, up 1.25% from the prior year.
• Depreciation & Amortization (CF) was $55.9 million for Q1 2026 at Vertex Pharmaceuticals, roughly flat from $55.7 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $59.0 million in Q4 2023 to a low of $35.9 million in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $47.2 million across 5 years, with a median of $48.4 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) soared 53.65% in 2023, then retreated 21.19% in 2024.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $38.4 million in 2022, then jumped by 53.65% to $59.0 million in 2023, then declined by 21.19% to $46.5 million in 2024, then rose by 19.78% to $55.7 million in 2025, then advanced by 0.36% to $55.9 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $55.9 million (Q1 2026), $55.7 million (Q4 2025), and $54.0 million (Q3 2025), per Business Quant data.